New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
05:18 EDTSLXPSalix, Pharming Group announces extension of PDUFA action date for Ruconest
Pharming Group NV and Salix Pharmaceuticals announced that the FDA has extended the Prescription Drug User Fee Act, or PDUFA, Action Date to July 16 for the company's Biologics License Application, or BLA, for the investigational drug Ruconest 50 IU/kg. Pharming and Salix are seeking U.S. marketing approval of Ruconest for the treatment of acute angioedema attacks in patients with hereditary angioedema.
News For SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
12:34 EDTSLXPSalix mentioned as a potential acquisition target by dealReporter
November 14, 2014
10:00 EDTSLXPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:03 EDTSLXPSalix upgraded to Buy from Neutral at UBS
UBS upgraded Salix Pharmaceuticals to Buy saying it believes management has a better handle on inventory levels than investors think. The sees opportunity at current share levels and lowered its price target for shares to $116 from $160.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use